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and care of all patients with COVID-19 
who receive CPAP and patients who 
are subsequently admitted to intensive 
care units for mechanical ventilation. 
Appropriate nutritional support—
including the introduction of paren-
teral nutrition, if necessary—improves 
outcomes in analogous cases.6
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Staff might also fear that the use of 
nasogastric feeding can cause mask 
air leaks or promote gastric distension 
and aspiration due to aerophagia.
Such issues are in fact readily 
managed, and the British Association 
for Parenteral and Enteral Nutrition 
has produced practical guidelines.2 
However, NHS England and NHS 
Improvement3 advocate opioid admin-
istration when CPAP is used to reduce 
the sensation of breathlessness and 
high tidal volumes,an intervention that 
can impair gut motility.
We received reports of three patients 
with COVID-19 who were treated 
with CPAP and developed starvation 
ketosis and other patients who have 
gone for extended periods (up to 
25 days) without substantial oral intake 
or initiation of nutritional support. The 
negative effects of malnutrition can 
be worsened by the process of muscle 
wasting, which is common in patients 
with COVID-19 who are admitted to 
hospital, and by subsequent admis sion 
to an intensive care unit for mechanical 
ventilation, where gut function might 
be impaired (eg, by use of opioid 
analgosedation), as dietitians have 
reported to the Critical Care Specialist 
Group of the British Dietetic Association.
We were also made aware of the 
use of 0·9% saline in some health-
care centres as the routine (and 
sole) intravenous crystalloid. Such 
practice does not comply with the 
National Institute for Health and 
Care Excellence clinical guideline 174: 
although 0·9% saline can be used for 
replacement of gastrointestinal losses 
or as a bolus for acute resuscitation, 
its use is not recommended in terms 
of routine maintenance.4 Use as 
routine maintenance can increase 
sodium and chloride load in the 
body, potentially leading to bowel 
oedema and further impairment of 
gastrointestinal function.5
We recommend that health-
care professionals with expertise in 
nutrition, especially dietitians, nutrition 
nurses, physicians, and pharmacists, 
should be engaged in the assessment 
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Malnutrition risk in 
hospitalised COVID-19 
patients receiving CPAP
Continuous positive airway pressure 
(CPAP) that is delivered by face 
mask or hood is increasingly used in 
patients with COVID-19 who have 
been admitted to hospital, often on 
general or respiratory wards. Oral 
intake of food and drink in patients 
with COVID-19 might have been and 
will often continue to be poor due to 
disease-associated anorexia, nausea, 
and impairment of taste. Full-face or 
hood CPAP also makes it impossible 
to eat and drink without mask 
removal,1 which can be associated with 
decreased arterial oxygen saturation. 
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Free licensing of 
vaccines to end the 
COVID-19 crisis
The pace of COVID-19 vaccine 
development, authorisation, and 
production is unprecedented. Yet all 
three approved vaccines by Pfizer–
BioNTech, Moderna, and AstraZeneca 
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to COVID-19 vaccines, but this 
approach could boost production 
in the immediate future. It would 
also enable vaccine manufacturers 
in low-income regions to start 
producing immediately,5 especially 
benefiting those countries that are 
far down the list to receive vaccines. 
Delays in vaccine production and 
deployment will lead to avoidable 
morbidity, mortality, and repeated 
lockdowns with detrimental health, 
social, and economic consequences 
that are related to COVID-19. Effective 
and coordinated roll-out plans 
are urgently required to speed up 
deployment of existing vaccines. The 
EU should also use all instruments that 
are available, including compulsory 
licensing, to overcome the delays in 
vaccine production and to protect 
public health in this unprecedented 
crisis.
Throughout the pandemic, things 
that were once considered to be 
impossible, such as lockdowns and 
other severe restrictions on personal 
and economic liberty, have become 
accepted. There is no reason why our 
approach to vaccine development and 
manufacture should be any different.
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are already facing manufacturing 
delays. These delays are creating 
chaos for many national vaccination 
programmes, leading to calls for 
coordinated efforts by governments 
and manufacturers to increase 
production.1
These pharmaceutical companies 
have benefited greatly from huge 
sums of public funding for research 
and development and advance pur-
chase commitments, amounting to 
between US$2·2 billion and $4·1 billion 
(by Feb 1, 2021) from Germany, the 
UK, and North America combined 
(appendix). Yet unfortunately, these 
governments did not make their 
support conditional on measures 
that would enable more vaccine to 
be produced through, for example, 
patent pools (eg, the COVID-19 
Technology Access Pool) or non-
exclusive licensing, which would allow 
pharmaceutical companies with spare 
manufacturing capacity to increase 
supply. So far, most effort has gone 
into increasing production capacity in 
the vaccine developers’ own facilities 
or through subcontracts and licensing 
arrangements with other developers, 
such as AstraZeneca’s agreement with 
the Serum Institute of India, or Sanofi’s 
support in filling and packing bottles of 
Pfizer–BioNTech’s vaccine.
It is not, however, too late to take 
bold measures to increase production. 
Ideally, an agreement could be reached 
with the patent holders to make 
the relevant intellectual property 
available. However, if this agreement 
is not possible, compulsory licensing 
is possible (ie, when a government 
grants permission to someone else 
to produce a patented product).2 
Compulsory licensing is permitted 
in exceptional circumstances: public 
health emergencies,3 such as the 
COVID-19 pandemic.
Together, thirteen EU member 
states account for more than 60% of 
the world’s major facilities for vaccine 
production and 90% of global vaccine 
production.4 Of course, changes would 
be needed to refocus production 
See Online for appendix
Guidelines should not 
pool evidence from 
uncomplicated and 
severe COVID-19
The WHO Global Development Group 
guidelines on COVID-19 therapeutics 
are meant to provide evidence-
based advice to all countries on the 
medical management of patients 
with COVID-19.1,2 The only small-
molecule drug to show unequivocal 
benefit to date is dexamethasone. In 
the largest randomised controlled 
trial in patients who were admitted 
to hospital with COVID-19 (ie, the 
RECOVERY trial), dexamethasone 
at a low dose reduced mortality in 
the prospectively defined subgroups 
of patients requiring medical 
oxygen (rate ratio 0·82 [95% CI 
0·72–0·94]) or being ventilated (0·64 
[0·51–0·81]) but not in patients 
not receiving respiratory support at 
randomisation (1·19 [0·91–1·55]).3 
The current WHO living guideline on 
COVID-19 therapeutics1 recognises this 
important difference in therapeutic 
response in relation to stage of the 
disease by recommending use of 
corticosteroids in patients requiring 
respiratory support but conditionally 
recommending against their use in 
patients not requiring respiratory 
support. By stark contrast, largely 
on the basis of inpatient studies, the 
guideline has recommended strongly 
against hydroxychloroquine (87·4% 
[9549 of 10 921] of studied patients 
were inpatients1) and lopinavir–
ritonavir (all 7429 patients were 
inpatients1) in patients with any 
disease severity. There is convincing 
evidence that these drugs do not 
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